Corcept Therapeutics

Bragar Eagel & Squire, P.C. Is Investigating CareDx, Medallion, Cortexyme, and Corcept and Encourages Investors to Contact the Firm

Retrieved on: 
Monday, May 2, 2022
Office of Inspector General, U.S. Department of Health and Human Services, DOJ, Corcept Therapeutics, U.S. Securities and Exchange Commission, Sale, Patient, Letter, FDA, HIPAA, IND, Therapy, GLOBE, CORT, Investigational New Drug, Medal, Food, HuffPost, Accountability Act, CDNA, Company, U.S. Department of Justice Office of Legislative Affairs, News, Alpha, Record, NASDAQ, SEC, District, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Health Insurance Portability and Accountability Act, Online gambling, Audit, Animal, Pharmaceutical industry, P.C

Our investigations concern whether these companies have violated the federal securities laws and/or engaged in other unlawful business practices.

Key Points: 
  • Our investigations concern whether these companies have violated the federal securities laws and/or engaged in other unlawful business practices.
  • The DOJ is investigating business practices related to CareDxs kidney testing and phlebotomy services.
  • On this news, Medallions stock fell up to 27% during intraday trading on December 29, 2021, thereby injuring investors.
  • For more information on the Corcept investigation go to: https://bespc.com/cases/CORT
    About Bragar Eagel & Squire, P.C.

Corcept Therapeutics to Announce First Quarter Financial Results, Provide Corporate Update and Host Conference Call

Retrieved on: 
Thursday, April 28, 2022
Patient, NASDAQ, Weight gain, Liver disease, GLOBE, Corcept Therapeutics, Investor, CORT, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Food, Pharmaceutical industry

MENLO PARK, Calif., April 28, 2022 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT) today announced it will report first quarter financial results and provide a corporate update on May 5, 2022.

Key Points: 
  • MENLO PARK, Calif., April 28, 2022 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT) today announced it will report first quarter financial results and provide a corporate update on May 5, 2022.
  • The company will also host a conference call that day at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time).
  • Alternatively, you may dial 1-833-693-0540 from the United States or 1-661-407-1581 internationally approximately 15 minutes before the start of the call.
  • A replay will be available through May 12, 2022, at 1-855-859-2056 from the United States and 1-404-537-3406 internationally.

Bragar Eagel & Squire, P.C. Is Investigating Cortexyme, Corcept, RBB, and Verra and Encourages Investors to Contact the Firm

Retrieved on: 
Tuesday, April 26, 2022
Royal Business Bank, News, Health Insurance Portability and Accountability Act, Letter, CEO, Investigational New Drug, U.S. Securities and Exchange Commission, IND, Accountability Act, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, NASDAQ, Food, District, GLOBE, Sale, Patient, Form 10-K, EVP, HIPAA, Mission statement, Corcept Therapeutics, Company, CORT, SEC, RBB, FDA, Record, Online gambling, Pharmaceutical industry, Audit, P.C

Our investigations concern whether these companies have violated the federal securities laws and/or engaged in other unlawful business practices.

Key Points: 
  • Our investigations concern whether these companies have violated the federal securities laws and/or engaged in other unlawful business practices.
  • On this news, Cortexymes stock price fell $44.17 per share, or 76.58%, to close at $13.51 per share on October 27, 2021.
  • On this news, Verra Mobilitys stock dropped as much as 7.6% during intraday trading on February 28, 2022, thereby injuring investors.
  • For more information on the Verra investigation go to: https://bespc.com/cases/VRRM
    About Bragar Eagel & Squire, P.C.

Bragar Eagel & Squire, P.C. Is Investigating Cortexyme, SelectQuote, Corcept, and Core Scientific and Encourages Investors to Contact the Firm

Retrieved on: 
Thursday, April 21, 2022
Health Insurance Portability and Accountability Act, News, Letter, Investigational New Drug, U.S. Securities and Exchange Commission, IND, Accountability Act, CRTX, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, NASDAQ, Food, District, GLOBE, Sale, Patient, HIPAA, Corcept Therapeutics, Company, CORT, Mining, NYSE, Research, FDA, Record, Medicare, Online gambling, Pharmaceutical industry, Renewable energy, Audit, Animal, P.C

Our investigations concern whether these companies have violated the federal securities laws and/or engaged in other unlawful business practices.

Key Points: 
  • Our investigations concern whether these companies have violated the federal securities laws and/or engaged in other unlawful business practices.
  • On this news, Cortexymes stock price fell $44.17 per share, or 76.58%, to close at $13.51 per share on October 27, 2021.
  • On this news, Core Scientifics stock fell $0.72, or 9%, to close at $6.98 on March 3, 2022, thereby injuring investors.
  • For more information on the Core Scientific investigation go to: https://bespc.com/cases/CORZ
    About Bragar Eagel & Squire, P.C.

Bragar Eagel & Squire, P.C. Is Investigating Corcept, Core Scientific, Anavex, and Roblox and Encourages Investors to Contact the Firm

Retrieved on: 
Saturday, April 16, 2022
Pedophilia, Health Insurance Portability and Accountability Act, News, U.S. Securities and Exchange Commission, Accountability Act, NASDAQ, Ageing, Rett syndrome, District, GLOBE, Sale, Bear's Cave (Erpfingen), Blog, HIPAA, Corcept Therapeutics, Social media, Roblox Corporation, Company, CORT, Mining, Sex, NYSE, Research, Website, Safety, Bears' Cave, Record, Therapy, P.C, Online gambling, Animal, Audit

Our investigations concern whether these companies have violated the federal securities laws and/or engaged in other unlawful business practices.

Key Points: 
  • Our investigations concern whether these companies have violated the federal securities laws and/or engaged in other unlawful business practices.
  • On this news, Core Scientifics stock fell $0.72, or 9%, to close at $6.98 on March 3, 2022, thereby injuring investors.
  • For more information on the Roblox investigation go to: https://bespc.com/cases/RBLX
    About Bragar Eagel & Squire, P.C.
  • The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country.

Bragar Eagel & Squire, P.C. Is Investigating Medallion, Cortexyme, SelectQuote, and Corcept and Encourages Investors to Contact the Firm

Retrieved on: 
Monday, April 11, 2022
Company, Therapy, Letter, NASDAQ, Sale, Record, Investigational New Drug, Corcept Therapeutics, NYSE, IND, Accountability Act, SEC, Medal, Health Insurance Portability and Accountability Act, CRTX, CORT, Food, District, HuffPost, U.S. Securities and Exchange Commission, Alpha, HIPAA, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, GLOBE, Medicare, News, FDA, Patient, Online gambling, Animal, Pharmaceutical industry, Renewable energy, Audit, P.C

Our investigations concern whether these companies have violated the federal securities laws and/or engaged in other unlawful business practices.

Key Points: 
  • Our investigations concern whether these companies have violated the federal securities laws and/or engaged in other unlawful business practices.
  • On this news, Medallions stock fell up to 27% during intraday trading on December 29, 2021, thereby injuring investors.
  • For more information on the Corcept investigation go to: https://bespc.com/cases/CORT
    About Bragar Eagel & Squire, P.C.
  • The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country.

Bragar Eagel & Squire, P.C. Is Investigating Corcept and Core Scientific and Encourages Investors to Contact the Firm

Retrieved on: 
Tuesday, April 5, 2022
Company, Therapy, NASDAQ, Sale, Record, Corcept Therapeutics, Mining, Accountability Act, Health Insurance Portability and Accountability Act, Research, CORT, District, U.S. Securities and Exchange Commission, HIPAA, GLOBE, News, Online gambling, Animal, P.C

NEW YORK, April 04, 2022 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Corcept Therapeutics, Inc. (NASDAQ: CORT) and Core Scientific, Inc. (NASDAQ: CORZ).

Key Points: 
  • NEW YORK, April 04, 2022 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Corcept Therapeutics, Inc. (NASDAQ: CORT) and Core Scientific, Inc. (NASDAQ: CORZ).
  • Corcept further disclosed that [t]he NJ USAO has informed Corcept that it is investigating whether any criminal or civil violations by Corcept occurred in connection with the matters referenced in the subpoena.
  • On this news, Core Scientifics stock fell $0.72, or 9%, to close at $6.98 on March 3, 2022, thereby injuring investors.
  • For more information on the Core Scientific investigation go to: https://bespc.com/cases/CORZ
    About Bragar Eagel & Squire, P.C.

Corcept Therapeutics Completes Enrollment in Phase 2 GRATITUDE Study of Miricorilant in Patients with Antipsychotic-Induced Weight Gain

Retrieved on: 
Monday, April 4, 2022
Risk, Journal, Human, Risperidone, Columbia University Irving Medical Center, Bipolar disorder, NASDAQ, Lists of diseases, Pharmacokinetics, New York State Psychiatric Institute, Overalls, Adult, Corcept Therapeutics, SEC, Columbia University, Patient, Health, CORT, Food, Schizophrenia, Safety, Intention, Goal, Liver disease, COVID-19, Intellectual property, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, GLOBE, Disorder, Depression, Weight gain, Data, Pharmaceutical industry

GRATITUDE is evaluating the efficacy, pharmacokinetics and safety of miricorilant among adult patients with schizophrenia or bipolar disorder and recent antipsychotic-induced weight gain.

Key Points: 
  • GRATITUDE is evaluating the efficacy, pharmacokinetics and safety of miricorilant among adult patients with schizophrenia or bipolar disorder and recent antipsychotic-induced weight gain.
  • Patients were randomized 1:1 to receive either 600 milligrams of miricorilant or placebo each day, in addition to their established dose of antipsychotic medication, for 12 weeks.
  • Earlier this year, Corcept completed enrollment in a second study, GRATITUDE II, which is evaluating miricorilant as a treatment for long-standing antipsychotic-induced weight gain.
  • The primary endpoint in both GRATITUDE and GRATITUDE II is reduction in body weight compared to patients receiving placebo.

Moore Kuehn, PLLC Encourages Investors of CORT and CACC to Contact Law Firm

Retrieved on: 
Thursday, March 31, 2022
District court, CORT, GLOBE, Company, Wall Street, Corcept Therapeutics, Advertising, PLLC, Telephone, Credit Acceptance, CACC, Bank

U.S. District Court Judge Lucy H. Koh denied defendants motion to dismiss the class action complaint, paving the way for litigation to proceed against Corcept and certain insider defendants.

Key Points: 
  • U.S. District Court Judge Lucy H. Koh denied defendants motion to dismiss the class action complaint, paving the way for litigation to proceed against Corcept and certain insider defendants.
  • On September 1, 2021, the Company announced that it agreed to pay over $27 million to settle litigation brought against it by the Massachusetts Attorney General.
  • If you own CORT or CACC please contactJustin Kuehn, Esq.by email at [email protected] or telephone at (212) 709-8245.
  • Moore Kuehn is aNew York-based law firm with attorneys representing investors and consumers.

Bragar Eagel & Squire, P.C. Is Investigating Corcept, Verra, Core Scientific, and Lilium and Encourages Investors to Contact the Firm

Retrieved on: 
Thursday, March 31, 2022
Company, Cell, Therapy, Form 10-K, Mission statement, NASDAQ, Sale, Record, Iceberg, Jet, Corcept Therapeutics, Lilium Jet, Mining, Accountability Act, SEC, Lilium, Health Insurance Portability and Accountability Act, Research, CORT, District, EVTOL, U.S. Securities and Exchange Commission, HIPAA, GLOBE, General Motors, News, NV, Online gambling, Animal, Audit, P.C

Our investigations concern whether these companies have violated the federal securities laws and/or engaged in other unlawful business practices.

Key Points: 
  • Our investigations concern whether these companies have violated the federal securities laws and/or engaged in other unlawful business practices.
  • On this news, Corcepts stock price fell $3.71 per share, or 16.91%, to close at $18.23 per share on December 8, 2021.
  • On this news, Core Scientifics stock fell $0.72, or 9%, to close at $6.98 on March 3, 2022, thereby injuring investors.
  • For more information on the Lilium investigation go to: https://bespc.com/cases/LILM
    About Bragar Eagel & Squire, P.C.